Novo Nordisk A/S (ADR) (NVO)
$66.15
0.05 (+0.08%)
| CAPS Rating |
|
|---|---|
| Open | $66.15 |
| Previous Close | $66.10 |
| Daily Range | $65.83 - $66.42 |
| 52-Week Range | $41.35 - $67.16 |
| Market Cap | $41.94B |
| P/E Ratio | 26.87 |
| Dividend (Yield) | 0.78 (1.20%) |
| Volume | 66,053 |
| Average Daily Volume | 160,000 |
How do you think NVO will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NVO Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NVO News and Commentary
- Can This Stock Go Higher? – The Motley Fool
- Secure Your Future Forever With These Stocks – The Motley Fool
- Music to Health-Care Investors' Ears – The Motley Fool
- Shrugging Off the Side Effects – The Motley Fool
- 5-Star Stocks Poised to Pop: Novo Nordisk – The Motley Fool
- Warning: Potential Blockbuster Ahead – The Motley Fool
- 3 Stocks Hitting High Notes – The Motley Fool
- 7 Shots at Superior Returns – The Motley Fool
- The Boring Old Trick That Makes You Money – The Motley Fool
- The Blockbuster Around the Corner – The Motley Fool
- The Magic of the Earnings Yield – The Motley Fool
- The Best Reason to Save – The Motley Fool
- Lantus Results: Reply Hazy, Try Again Later – The Motley Fool
- MannKind Needs More Leaps – The Motley Fool
- Your Stocks Just Got Riskier – The Motley Fool
- For the RECORD ... – The Motley Fool
- Best of Both Worlds – The Motley Fool
- Joining to Treat, and Beat, Diabetes – The Motley Fool
- Will These Drugs Get Past the FDA? – The Motley Fool
- I'm Rich! I'm Ruined! Overreaction Equals Opportunity – The Motley Fool


RSS Headlines
Fool UK